anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study conducted a randomized controlled clinical trial with an intention to enroll 80 insomnia participants. Participants were randomly assigned in a 1:1:1:1 ratio to four groups:1）taVNS combined with slow breathing group；2）taVNS with normal breathing group；3）slow breathing with sham taVNS group；4）normal breathing with sham taVNS group.The study included a one-week baseline period, a two-week treatment period, and a two-week follow-up period. During the 2-week treatment period, 20 minutes of continuous treatment was performed every evening. The stimulation parameters were set to 20Hz, 200μs, 5s ON-5s OFF and a burst frequency of 2000Hz. For taVNS combined with slow breathing group,after preparing the skin, electrodes were attached to the tragus and cymba conchae of the left ear,and under the guidance of the device\'s video, the participants were instructed to perform six slow and relaxed breaths per minute (0.1Hz), while the device delivered stimulation during the 5 seconds of exhalation.For taVNS with normal breathing group,without video guidance on the device, the participants breathed freely while receiving normal taVNS intervention.For slow breathing with sham taVNS group,the participants followed the video instructions to perform slow breathing while wearing the stimulation electrodes, but the device only outputted stimulation for one minute.For normal breathing with sham taVNS group,the device outputted stimulation for only one minute, and the participants breathed normally. EEG and ECG data were collected before and after the 2-week treatment, and scale data were collected before and after the treatment as well as at the end of follow-up. Sleep diaries were recorded throughout the 5-week period.
The study will consist of a screening period in which patient eligibility will be determined and baseline assessments performed. Once eligibility is confirmed, patients will be enrolled within 4 weeks of baseline imaging to receive either TURP or PAE with Embosphere Microspheres. After treatment, patients will return for follow-up visits at Months 1, 3, 6, and 12. At each of these visits patients will complete IPSS and IIEF questionnaires and have a physical exam, laboratory assessments (including PSA), a DRE, and a transrectal ultrasound of the prostate. At each visit patients will have a cystoscopy and proctoscopy if medically indicated. Cystoscopy is necessary in all cases of hematuria (injury associated with bleeding). Proctoscopy is necessary in all cases of bleeding per the rectum. An MRI of the prostate will be conducted at the 3 and 12 month visits. Uroflowmetry testing will be performed at the 1 and 12 month visits, and at other visits if medically indicated. MRIs will be assessed by blinded Central Reviewers.

The primary endpoint will be improvement of symptoms from BPH evaluated using the IPSS at 12 months post treatment. Patients will continue to be followed annually for up to 4 additional years. At a minimum, patients will be requested to complete the IPSS and International Index of Erectile Dysfunction (IIEF) questionnaires by telephone, email or mail once per year during this long term follow up period. Patients who are willing to return to the clinic will have a physical exam, MRI of the prostate, digital rectal exam (DRE), transrectal ultrasound of the prostate, PSA, and uroflowmetry testing performed each year. Treatments for LUTS due to BPH after the study treatment and 12 month follow up are complete will be documented during the long term follow up period to the extent possible. This long term follow up data will be summarized and submitted separately from the data for the initial 12 months of this study.

Safety will be evaluated throughout the initial 12 months of the study by assessing adverse events, as well as changes in laboratory values, and findings on physical examination. Concomitant medication usage will be assessed. A follow up ECG will be performed at the 12 month visit.

Patient recruitment is anticipated to take approximately 2 years. Duration of each patient's participation is expected to be 5 years, including a 4 year long term follow up period. The total duration of the study will be approximately 7 years, including long term follow up.
Soil-borne cereal mosaic virus (SBCMV), the causative agent of wheat mosaic, is a Furovirus challenging wheat production all over Europe. Differently from bread wheat, durum wheat shows greater susceptibility and stronger yield penalties, so identification and genetic characterization of resistance sources are major targets for durum genetics and breeding. The Sbm1 locus providing high level of resistance to SBCMV was mapped in bread wheat to the 5DL chromosome arm (Bass in Genome 49:1140-1148, 2006). This excluded the direct use of Sbm1 for durum wheat improvement. Only one major QTL has been mapped in durum wheat, namely QSbm.ubo-2B, on the 2BS chromosome region coincident with Sbm2, already known in bread wheat as reported (Bayles in HGCA Project Report, 2007). Therefore, QSbm.ubo-2B = Sbm2 is considered a pillar for growing durum in SBCMV-affected areas. Herein, we report the fine mapping of Sbm2 based on bi-parental mapping and GWAS, using the Infinium 90 K SNP array and high-throughput KASP®. Fine mapping pointed out a critical haploblock of 3.2 Mb defined by concatenated SNPs successfully converted to high-throughput KASP® markers coded as KUBO. The combination of KUBO-27, wPt-2106-ASO/HRM, KUBO-29, and KUBO-1 allows unequivocal tracing of the Sbm2-resistant haplotype. The interval harbors 52 high- and 41 low-confidence genes, encoding 17 cytochrome p450, three receptor kinases, two defensins, and three NBS-LRR genes. These results pave the way for Sbm2 positional cloning. Importantly, the development of Sbm2 haplotype tagging KASP® provides a valuable case study for improving efficacy of the European variety testing system and, ultimately, the decision-making process related to varietal characterization and choice.
PURPOSE: A bilayered pharmaceutical composite containing an HMG-CoA reductase inhibitor and irbesartan is provided to improve the availability of a drug and an elution rate. CONSTITUTION: A bilayered pharmaceutical composite comprises a first layer and a second layer. The first layer contains irbesartan or a pharmaceutically acceptable salt thereof. The second layer contains an HMG-CoA reductase inhibitor and a basic additive. The inhibitor is selected from a group consisting of rosuvastatin, lovastatin, atorvastatin, pravastatin, fluvastatin, pitavastatin, simvastatin, rivastatin, cerivastatin, velostatin, mevastatin, a pharmaceutically acceptable salt thereof, a precursor thereof, and a mixture thereof. [Reference numerals] (AA) Bilayered pharmaceutical composite; (BB) Second layer: atorvastatin layer + basic additive; (CC) First layer: irbesartan layer
Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
The preparation for treating vaginosis of bacterial origin comprises the live bacterial mass as the active ingredient, the protective medium, and the fatty base. Lactobacillus and several species of the eubiotic bacteria belonging to bifidobacteria, streptococci, and lactococci are used. One dose of preparation contains 105-109 bacterial bodies. In addition, the preparation contains the acceptable sorbent at a (9-1) : (1-9) ratio and the biologically active additive amounting to 0.05-3.0 mass %. The acceptable fatty base with pH 4.5-7.0 contains no more than 5 mass % of water. The manufacturing process comprises the growth of the appropriate bacterial mass of each bacterium, their immobilization on the acceptable sorbent, the addition of the protective medium and the biologically active additive. The product is then freeze-dried, with the mode of freeze-drying being correspondent to thatrecommended for each bacterial species used in the mixture. The dry preparation is finally mixed with the acceptable fatty base.
This is a Phase 2, open-label, single arm, multi-center, study of orally administered tivozanib to approximately 100 subjects with advanced renal cell carcinoma (RCC). This study is designed to evaluate biomarkers in blood and archived tissue samples, and their correlation with clinical activity and/or treatment-related toxicity in subjects with advanced RCC, and estimate the percentage of tivozanib-treated subjects who are progression-free at 6 months, overall response rate (ORR), progression free survival (PFS), safety and tolerability, and pharmacokinetics (PK). Subjects will be stratified by histology (clear cell vs. non-clear cell). Enrollment of non-clear cell subjects will be limited to ≤ 30% of the entire study population.

Study enrollment is anticipated to complete in approximately 9 months. Treatment duration is estimated to last approximately 6 months from the subject's first dose of tivozanib with a follow-up period of 30 days. After 6 months, treatment with tivozanib may continue by participation in a rollover protocol (AV-951-09-901). Maximum duration of subject participation in this Phase 2 study is approximately 8 months.
The invention discloses a polysubstituted 3, 3'-dipyrrole, its derivative and preparation method. The compound is shown as formula I. The method comprises the steps of: mixing a solution of anhydrous iron trihalide with a solution of a pyrrole compound shown in formula II to let them react so as to obtain the product. The method has the characteristics that: (1) a coupling reaction aid is cheap, and the reaction conditions are mild. The iron halide aid adopted in the invention is cheap and easily available; and the reaction is carried out at room temperature; (2) the reaction has a high atom utilization rate. Oxidative dehydrogenation coupling reaction of two-molecule pyrrole only removes monomolecular hydrogen; and (3) the reaction is simple and convenient, and the substrate has wide universality. Only polysubstituted pyrrole is used as the raw material, iron trihalide is employed as the aid, and there is no need for any other additive. The product of the reaction can be separated by column chromatography. The reaction is applicable to a variety of substrates including various substrates with alkyl or aryl, electron-donating or electron-withdrawing groups.
The present invention relates to a cleaning composition having a foam boosting silicone. More particularly, it relates to a cleaning composition having lower concentration of detersive surfactant and the foam boosting silicone. It is an object of the present invention to provide cleaning composition that provide enhanced sensory properties to the consumer. Thus, it also is an object of the present invention to provide cleaning composition providing enhanced foam stability, in particular without increasing the amount of detergent surfactants. Desirably, the enhanced foam stability is provided upon dilution of the cleaning composition when it is used. We have found that one or more of these objects can be achieved by the cleaning composition of the present invention. In particular, it was surprisingly found that a siloxane having 19 to 30 oxyalkylene group can be used to provide cleaning composition that preferably upon dilution display good foamability and longer lasting foams. The composition provides stable foam and good cleansing with lesser amounts of surfactant.
A micro-particle structure containing ingredients of burdock compound for protecting gastric mucosa so as to improve the health of the stomach is provided. The micro-particle structure from the inside thereof includes a core body protecting gastric mucosa and an exterior structure body in order. The core body includes burdock concentrate, fucoidan, and a probiotic additive including lactic acid bacteria. The exterior structure body from the inside thereof includes an encapsulation body and a protective layer. The encapsulation body encapsulates the core body. The protective layer has a membrane-shaped structure, encapsulating the encapsulation body, for protecting the activity of functional ingredients.
Shaving lotion kits and methods of preparing skin and unwanted hair for shaving prepare skin and unwanted hair for shaving without requiring cleanup. This is critical when water, soap, or towels are unavailable. The user can conveniently shave any area of the body, even when water is not accessible, such as when resting in a hospital bed or while camping. The shaving lotion kit also creates less mess than dispensing shaving cream from a can into the hand. Shaving lotion that is not removed during the shaving process can simply be rubbed into the skin. Unlike shaving creams, the shaving lotion also has vitamins and sunscreen to protect the skin and promote skin health.
Pomalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of pomalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. In vitro, in the presence of drug, substrate proteins (including Aiolos and Ikaros) are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation of lenalidomide-resistant multiple myeloma (MM) cell lines and synergized with dexamethasone in both lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell apoptosis. Pomalidomide enhanced T cell- and natural killer (NK) cell-mediated immunity and inhibited production of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. Pomalidomide demonstrated anti-angiogenic activity in a mouse tumor model and in the in vitro umbilical cord model.
The Mobile Intervention. 20 hours of training consisting of 10 hours of cognitive training exercises plus 10 hours of social cognitive training exercises will be delivered over the course of 12 weeks in addition to PRIME. Participants may choose to complete study activities in person at their coordinated specialty care program or may choose to complete study activities remotely.
This disclosure relates to systems and methods for providing individualized assessments of breast cancer. The assessments are provided in the format of index scores that are prognostic to disease severity and progression. Methods involve measuring gene expression from a patient sample to create a gene expression signature. The gene expression signature is compared with expression signatures from tumors that are associated with known outcomes. The comparison is used to generate an index score that assigns a risk status to the patient. The index score may indicate, for example, risk of distant metastasis or benefit of chemotherapy.
To minimize the risk of hypoglycemia, the initial dosing, dose increments and maintenance dosage of pioglitazone and glimepiride tablets should be conservative. During initiation of pioglitazone and glimepiride tablet therapy and any subsequent dose adjustments, these patients should be observed carefully for hypoglycemia.

A multiple-dose titration study was conducted in 16 patients with type 2 diabetes and renal impairment using doses ranging from 1 mg to 8 mg daily for three months. Baseline creatinine clearance ranged from 10 to 60 mL/min. The pharmacokinetics of glimepiride were evaluated in the multiple-dose titration study and the results were consistent with those observed in patients enrolled in a single-dose study. In both studies, the relative total clearance of glimepiride increased when kidney function was impaired. Both studies also demonstrated that the elimination of the two major metabolites was reduced in patients with renal impairment [see Clinical Pharmacology (12.3)].
Although tarry stool is a common feature of peptic ulcer bleeding, it can also be a manifestation of lower gastrointestinal (GI) bleeding. Examples include colonic cancer, small bowel tumors, and small or large bowel ulcers induced by aspirin or painkillers (NSAIDs). However, clinicians are often misled by the finding of peptic ulcers as the source of GI bleeding. It is not uncommon to detect peptic ulcers incidentally but the source of bleeding is actually in the lower GI tract (e.g. NSAID- or aspirin-induced small or large bowel bleeding ulcers, small bowel tumors, or colorectal cancer). Delay in diagnosis of lower GI bleeding often leads to serious consequences.

The preferred investigations for lower GI bleeding are colonoscopy plus video capsule endoscopy. Colonoscopy has been the gold standard for the diagnosis of colonic bleeding. The risk of colonoscopy-induced complications such as bleeding or perforation is less than 1 in 3500. Video capsule endoscopy is a non-invasive, safe and accurate technology that has been approved by the FDA for investigation of small bowel diseases. The video capsule is an 11x 26mm capsule that encases a digital camera, light-emitting diodes, batteries, and a transmitter. The patient needs to swallow the video capsule after an overnight fast and wear a recording device for eight hours. Images are taken twice-per-second and transmitted to the recording device. Oral feeding can be resumed after four hours. There is no restriction to daily activities. The swallowed capsule will be expelled naturally after 5 to 12 hours virtually in all patients. The risk of capsule retention is very low and only occurs in patients with severe small bowel stricture.

This study aims to assess the incidence and etiology of lower GI bleeding in patients presenting with tarry stool. The result will provide important information about the magnitude of the problem of lower GI bleeding that will improve our patient care.
OBJECTIVE: The study aimed to identify the effects of ground reaction forces (GRF) recorded during landing in typical elements of three dance styles, including classical, modern, and folk dance, on injuries` topography.
METHODS: The research involved a survey and measurements of GRF generated during landing after the jump. The survey involved a group of 90 professional dancers. In the questionnaire, the dancers marked areas of the human body that were affected at least once by injuries. Biomechanical tests of the GRF recording were conducted on a group of 15 professional dancers. The analysis focused on the following parameters: a maximum value of the vertical variable of the GRF relative to body weight (maxGRFz), the time between the moment from first foot contact with the ground to the moment of reaching the maxGRFz (tmaxGRFz), and the loading rate of the GRF relative to body weight (LRGRFz).
RESULTS: Regardless of dance style and sex, the lower spine, knee joints, ankle joints and feet were the areas most affected by injuries among professional dancers. The level of maxGRFz, tmaxGRFz and LRGRFz during typical jumps in classical, modern, and folk dance was statistically significantly different (P<0.01*). The highest mean maxGRFz values were recorded for jumps performed by classical dancers. Furthermore, the sum of injury-affected areas differed significantly across various dance styles and was connected with the impact forces transferred by the dancer's musculoskeletal system.
CONCLUSION: The level of GRF is one of the decisive factors affecting the topography of professional dance injuries.
For a device for continuous continual patient-monitoring, comprising can portable self-sustaining patient wear hub (PWH). PWH is designed to the compact conformation together with patient, lightweight device. Parameter measuring apparatus is connected to this PWH. Third party's parameter measuring apparatus is by using coupling assembling to be connected to PWH, and this coupling assembling becomes to embed the agreement in PWH by the information translation being provided by third party device. PWH can communicate by letter with bedside monitors by wire cable or by wireless mode. Measured value illustrates on external display and/or optional integrated PWH touch-screen display. PWH comprises the internal memory for store patient data and trend. PWH comprises the Docking station for operation and battery rechargeable electrical energy are provided alternatively. PWH is distributed to each patient, and in whole nursing process between multiple section office always together with this patient, therefore eliminated the demand of patient being carried out to rewiring.
PROBLEM TO BE SOLVED: To obtain the skin cosmetic excellent in water resistance and stability, good in extensivity, and accompanied by a refreshing touch by using both an alkyl-modified carboxyvinylpolymer exhibiting water repellency and a specific dimethylpolysiloxane. SOLUTION: A skin cosmetic contains the combination of an alkyl-modified carboxyvinylpolymer and a dimethylpolysiloxane having an average mol.wt. of >=50000. The dimethylpolysiloxane is preferably added in an amount of 0.05-50wt.% based on the whole amount of the skin cosmetic. The alkyl-modified carboxyvinylpolymer is preferably added in an amount of approximately 0.01-10wt.% based on the whole amount of the skin cosmetic. The cosmetic can further hold a skin roughness-improving effect over a long time and is little in adhesion to contact articles.
PROBLEM TO BE SOLVED: To obtain a dental restorative material having high condensability, low volume shrinkage, low shrinkage stress, etc., and excellent abrasion resistance by including a filler, a polymerizable acrylic monomer and a specific rheological modifier. SOLUTION: This dental restorative material is obtained by including (A) a filler, (B) a polymerizable acrylic monomer and (C) a rheological modifier in an amount effective in reducing the volume shrinkage of the dental restorative material at the time of polymerization, e.g. a hydroxy-functional polycarboxylic acid amide represented by the formula [R is a 6-60C aliphatic hydrocarbon or the like; R' is H, a 1-4C alkyl or the like; (x) is 1-3; (y) is 0 or 1; Z and Z' are each a different 2-6C alkylene free radical; Q is a 2-200C aliphatic hydroacrbon free radical; (n) is 2-3] [e.g. BYK-405 (R)]. In the above restorative material, the component C is preferably contained in an amount of about 0.1-1.5 wt.%. In addition to the above components, a phosphoric ester- based dispersing agent or a fluorocopolymer soluble in (meth)acrylate resins may be contained.